Regeneron Pharmaceuticals (REGN) stock price, revenue, and financials

Regeneron Pharmaceuticals market cap is $51.6 b, and annual revenue was $8.5 b in FY 2020

$51.6 B

REGN Mkt cap, 07-Apr-2021

$8.5 B

Regeneron Pharmaceuticals Revenue FY, 2020
Regeneron Pharmaceuticals Net income (FY, 2020)3.5 B
Regeneron Pharmaceuticals EBIT (FY, 2020)3.6 B
Regeneron Pharmaceuticals Cash, 31-Dec-20202.2 B
Regeneron Pharmaceuticals EV52.1 B

Regeneron Pharmaceuticals Revenue Breakdown

Embed Graph

Regeneron Pharmaceuticals revenue breakdown by business segment: 33.3% from Sanofi and Bayer Collaboration, 61.5% from Product Sales and 5.3% from Other

Regeneron Pharmaceuticals Income Statement

Regeneron Pharmaceuticals Balance Sheet

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

535.2m812.7m1.5b1.6b2.2b

Accounts Receivable

1.6b2.0b2.2b2.7b3.1b

Prepaid Expenses

130.5m225.0m243.3m387.1m160.8m

Inventories

399.4m726.1m1.2b1.4b1.9b

Current Assets

3.2b4.3b6.4b7.7b9.8b

PP&E

2.1b2.4b2.6b2.9b

Total Assets

7.0b8.8b11.7b14.8b17.2b

Accounts Payable

879.1m815.1m218.2m418.1m475.5m

Short-term debt

127.3m

Current Liabilities

1.2b1.1b1.4b2.1b2.7b

Long-term debt

351.6m703.5m708.5m713.9m2.7b

Total Debt

478.8m703.5m708.5m713.9m2.7b

Total Liabilities

2.5b2.6b3.0b3.7b

Common Stock

110.0k112.0k100.0k100.0k

Preferred Stock

Additional Paid-in Capital

3.0b3.5b3.9b4.4b6.7b

Retained Earnings

1.7b2.9b5.3b7.4b

Total Equity

4.4b6.1b8.8b11.1b11.0b

Debt to Equity Ratio

0.1 x0.1 x0.1 x0.1 x

Debt to Assets Ratio

0.1 x0.1 x0.1 x0 x

Financial Leverage

1.6 x1.4 x1.3 x1.3 x1.6 x

Regeneron Pharmaceuticals Cash Flow

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

895.5m1.2b2.4b2.1b3.5b

Depreciation and Amortization

104.7m145.5m148.2m210.3m235.9m

Accounts Receivable

(143.8m)(362.7m)(268.9m)(473.1m)(1.4b)

Inventories

(149.8m)(314.2m)(387.9m)(335.5m)(529.4m)

Accounts Payable

254.0m(23.2m)210.0m444.5m118.9m

Cash From Operating Activities

1.5b1.3b2.2b2.4b2.6b

Purchases of PP&E

(614.6m)

Capital Expenditures

(511.9m)(272.6m)(383.1m)(429.6m)

Cash From Investing Activities

(1.0b)(1.0b)(1.5b)(2.0b)(70.6m)

Long-term Borrowings

40.6m(19.9m)

Cash From Financing Activities

(700.4m)(24.4m)(77.1m)(252.1m)(2.0b)

Net Change in Cash

(273.9m)277.5m655.0m150.1m

Interest Paid

5.5m18.7m22.3m25.0m23.2m

Income Taxes Paid

481.4m754.8m205.6m342.3m188.1m

Free Cash Flow

961.5m1.0b1.8b2.0b

Regeneron Pharmaceuticals Ratios

USDFY, 2016

Revenue/Employee

900.1k

Debt/Equity

0.1 x

Debt/Assets

0.1 x

Financial Leverage

1.6 x

Regeneron Pharmaceuticals Operating Metrics

FY, 2016FY, 2017FY, 2018FY, 2019

Cell Culture Capacity, liters

97 k101 k100 k230 k

Facility Space Leased, sq. ft.

1.18 m1.47 m1.47 m1.47 m

Facility Space Owned, sq. ft.

1.56 m1.61 m1.61 m1.35 m

Patents (EU)

371111

Patents (US)

6171821

Product Candidates

16152122

Products

5677

Trademarks

891213

Regeneron Pharmaceuticals Employee Rating

4907 votes
Culture & Values
3.9
Work/Life Balance
3.6
Senior Management
3.6
Salary & Benefits
4.2
Career Opportunities
3.7
Source